Pooled international procurement of essential adult cancer medicines
Countries buying cancer drugs alone pay more and face shortages. Buying together, as they already do for childhood cancer drugs and vaccines, cuts prices and secures supply.
The WHO and St Jude Global Platform for Access to Childhood Cancer Medicines (2021) pools demand across countries for paediatric essential medicines; PAHO's Strategic Fund and Gavi do the same for other products. Adult essential oncology medicines on the WHO Model List (cisplatin, carboplatin, paclitaxel, docetaxel, tamoxifen, letrozole, imatinib, trastuzumab biosimilars and others) are procured nationally at widely varying prices. The proposal is a pooled procurement mechanism for these products covering low- and lower-middle-income countries, with multi-year volume guarantees, quality prequalification and a buffer stock against shortages.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Prices and value, Most of the world has almost no cancer care.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Imatinib, Prices and value, Most of the world has almost no cancer care.
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Most of the world has almost no cancer care.
- InstitutionCentral Drugs Standard Control Organization
Shares Imatinib, Trastuzumab, Prices and value, Most of the world has almost no cancer care.
- IdeaChoose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Most of the world has almost no cancer care.
- IdeaPublic-option manufacturing for essential generic cancer drugs in shortage
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Prices and value, Most of the world has almost no cancer care.